Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet 2012;380:601–610.CrossRefPubMedGoogle Scholar

Hu G, Joushilahti P, Tuomilehto J. Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Eur. Heart J. 2007; 28:3059–3066.CrossRefPubMedGoogle Scholar

Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Løchen ML, Löllgen H,Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WM. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2016;37:2315–81.CrossRefPubMedPubMedCentralGoogle Scholar

James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC, Svetkey LP, Taler SJ, Townsend RR, Wright JT, Narva AS, Ortiz E. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC8). JAMA 2014; 311:507–520.CrossRefPubMedGoogle Scholar

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2015;58:429–442.CrossRefPubMedGoogle Scholar

Chatzikyrkou C, Haller H, Menne J. Behandlungsziele bei Bluthochdruck und Diabetes mellitus. Kann medikamentöse Prävention übertrieben werden? Internist 2012;53:882–892.CrossRefPubMedGoogle Scholar

Williams B. Treating hypertension in patients with diabetes. When to start and how low to go ? JAMA 2015;313:573–574.CrossRefPubMedGoogle Scholar

The SPRINT Research Group A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373:2103–2116.CrossRefPubMedCentralGoogle Scholar

Gregg EW, Garfield S, Cheng J, Saydah S, Cowie C, Garfield S, Geiss L, Barker L. Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006. Findings from the National Health Interview Survey. Diabetes Care 2012;35:1252–1257.CrossRefPubMedPubMedCentralGoogle Scholar

Icks A, Dickhaus T, Hörmann A, Heier M, Giani G, Kuch B, Meisinger C. Differences in trends in estimated incidence of myocardial infarction in non-diabetic and diabetic people: Monitoring Trends and Determinants on Cardiovascular Diseases (MONICA)/Cooperative Health Research in the Region of Augsburg (KORA) registry. Diabetologia 2009;52:1836–1841.CrossRefPubMedGoogle Scholar

Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood Pressure Lowering in Type 2 Diabetes. A Systematic Review and Meta-analysis. JAMA 2015;313:603–615.CrossRefPubMedGoogle Scholar

Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52:2288–2298.CrossRefPubMedGoogle Scholar

Stratton IM, Cull CA, Adler AI, Matthews D, Neil A, Holman R. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006; 49:1761–1769.CrossRefPubMedGoogle Scholar

Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving HH, Pedersen O. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016;59:2298–2307.CrossRefPubMedPubMedCentralGoogle Scholar

ACCORD Study Group and ACCORD Eye Study Group. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. N Engl J Med 2010;363:233–244.CrossRefGoogle Scholar

Azadbakht L, Fard NRP, Karimi M, Baghaei MH, Surkan PJ, Rahimi M, Esmaillzadeh A, Willett WC. Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial. Diabetes Care 2011;34:55–57.CrossRefPubMedGoogle Scholar

Estruch R et al. for the PREDIMED Study Investigators* Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013; 368:1279–1290.CrossRefPubMedGoogle Scholar

Bonaccio M, Di Castelnuovo A, Costanzo S, Persichillo M, Donati MB, de Gaetano G, Iacoviello L. on behalf of the MOLI-SANI Study Investigators. Adherence to the traditional Mediterranean diet and mortality in subjects with diabetes. Prospective results from the MOLI-SANI study. European Journal of Preventive Cardiology 2016; 23:400–407.CrossRefPubMedGoogle Scholar

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117–2128.CrossRefPubMedGoogle Scholar

Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A“Thrifty Substrate” Hypothesis. Diabetes Care 2016;39:1108–1114.CrossRefPubMedGoogle Scholar

Anders HJ, Davis JM, Thurau K. Nephron Protection in Diabetic Kidney Disease. N Engl J Med 2016;375:2096–2098.CrossRefPubMedGoogle Scholar